文献速递妇科肿瘤

宫颈癌放化疗后替吉奥维持化疗:随机试验

Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.
PubMed 文献 · Eur J Cancer · 2025-02-15

这项多中心3期随机试验(GOTIC-002)纳入351例局部晚期宫颈癌患者,在根治性同步放化疗达到完全或部分缓解后,1:1随机分为观察组(178例)或替吉奥(UFT)维持治疗组(173例),UFT按体表面积300-400 mg/日口服2年。中位随访3年,5年无进展生存率观察组61.3%、UFT组62.0%(HR 0.92,P=.634),5年总生存率分别为77.6%和76.1%(HR 1.04,P=.869),UFT未改善无进展生存或总生存。

要点

  • 宫颈癌同步放化疗后UFT维持治疗未改善5年无进展生存(61.3% vs 62.0%,HR 0.92,P=.634)。
  • 5年总生存率两组相近(77.6% vs 76.1%,HR 1.04,P=.869)。
  • UFT组不良事件更常见(93.5% vs 73.9%,比值比5.05),多为轻至中度。

核心结论

  • 研究结果提示需重新考虑局部晚期宫颈癌同步放化疗后的维持治疗策略,可能从细胞毒性化疗转向其他方法以改善生存结局。

研究设计与样本

  • 多中心3期随机试验(GOTIC-002),2010年至2018年纳入351例Ib2-IVa期宫颈癌患者。
  • 同步放化疗后达到完全或部分缓解者按1:1随机分为观察组(178例)或UFT维持治疗组(173例)。
  • UFT按体表面积300-400 mg/日口服2年,直至疾病进展或出现不良事件。
  • 主要终点为无进展生存,总生存与安全性为次要终点。

主要发现

  • 中位随访3年,两组中位无进展生存均未达到。
  • 5年无进展生存率观察组61.3% vs UFT组62.0%(HR 0.92,P=.634)。
  • 5年总生存率观察组77.6% vs UFT组76.1%(HR 1.04,P=.869)。
  • UFT依从性范围为87.8%至98.8%。
  • UFT组不良事件更常见(93.5% vs 73.9%,比值比5.05),多为轻至中度。

关键数值与推荐

  • 5年无进展生存率:观察组61.3%,UFT组62.0%(HR 0.92,P=.634)。
  • 5年总生存率:观察组77.6%,UFT组76.1%(HR 1.04,P=.869)。
  • 不良事件发生率:观察组73.9%,UFT组93.5%(比值比5.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LACC), but recurrence rates remain high. This multicenter phase-3 randomized trial (GOTIC-002) evaluated the efficacy of low-dose oral tegafur-uracil (UFT) as maintenance chemotherapy following curative CCRT for LACC. METHODS: Between 2010 and 2018, 351 patients with stage Ib2-IVa cervical cancer were enrolled. After achieving complete or partial remission post-CCRT, patients were randomized 1:1 into observation (arm O) or UFT maintenance therapy (arm UFT). UFT doses were 300-400 mg/day based on body surface area for 2 years, disease progression or adverse effects occurred. The primary endpoint was progression-free survival (PFS), with overall survival (OS) and safety as secondary endpoints. RESULTS: Patient characteristics were similar between the groups (n = 178 in arm O, n = 173 in arm UFT). During a median follow-up of 3 years, median PFS was not reached in either group. 5-year PFS rates were similar between them (arm O: 61.3 %, arm UFT: 62.0 %, hazard ratio: 0.92, P = .634). 5-year OS rates were also comparable (77.6 % vs 76.1 %, hazard ratio: 1.04, P = .869). Compliance with UFT ranged from 87.8 % to 98.8 %. Although adverse events were more frequent in arm UFT (93.5 % vs 73.9 %, odds ratio: 5.05), most were mild or moderate. Despite its tolerability, UFT did not improve PFS or OS. CONCLUSIONS: These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hasegawa K, Nishio S, Yamamoto K, et al. Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial. Eur J Cancer. 2025. PMID: 40010135. doi:10.1016/j.ejca.2025.115304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。